Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

Hepatology

Volumn 64, Issue 2, 2016, Pages 370-380

  Kwo, Paul ^a   Gitlin, Norman ^b   Nahass, Ronald ^c   Bernstein, David ^d   Etzkorn, Kyle ^e   Rojter, Sergio ^f   Schiff, Eugene ^g   Davis, Mitchell ^h   Ruane, Peter ⁱ   Younes, Ziad ^j   Kalmeijer, Ronald ^k   Sinha, Rekha ^k   Peeters, Monika ^l   Lenz, Oliver ^l   Fevery, Bart ^l   De La Rosa, Guy ^k   Scott, Jane ^m   Witek, James ^k  

^a INDIANA UNIVERSITY   (United States)

^b Atlanta Gastroenterology Associates   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e Borland Groover Clinic   (United States)

^f NATIONAL RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h Digestive CARE South Florida Center of Gastroenterology   (United States)

ⁱ Ruane Medical and Liver Health Institute   (United States)

^j Gastro One   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^l JANSSEN RESEARCH FOUNDATION   (Belgium)

^m Janssen Global Services   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; INTERLEUKIN 28B; SIMEPREVIR; SOFOSBUVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MANIA; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; WHIPLASH INJURY;

EID: 84978953939     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28467     Document Type: Article

References (22)

1. Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 2014;34(Suppl. 1):60-68.
2. American Association for the Study of Liver Diseases. HCV guidance: recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org/full-report-view. Accessed May 5, 2015.
3. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015. Accessed May 5, 2015.
4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
5. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
6. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
7. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
8. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
9. Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508.
10. Radloff LS. A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
11. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
12. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010;54:1878-1887.
13. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
14. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359-365.
15. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
16. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
17. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.
18. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-1679.
19. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, et al. Simeprevir (TMC435) with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.
20. Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 [Abstract]. J Hepatol 2015;62:S263.
21. Scott J, Gilles L, Fu M, Brohan E, Panter C, Arbuckle R, et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. J Viral Hepat 2015;22:639-650.
22. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: scientific and regulatory approaches to clinical trial designs. Hepatology 2015;62:1298-1303.